Trial Profile
An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
- Indications Early breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 07 Jul 2021 Status changed from active, no longer recruiting to completed.
- 06 Apr 2021 Planned End Date changed from 28 Dec 2020 to 11 Jun 2021.
- 06 Apr 2021 Planned primary completion date changed from 28 Dec 2020 to 11 Jun 2021.